Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

(2012) S. M. Horwitz et al.   BLOOD

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Romidepsin

(2011) Lily P.H. Yang   DRUGS

Romidepsin: a novel histone deacetylase inhibitor for cancer

(2011) Erin M Bertino et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance

(2011) Robert W. Robey et al.   MOLECULAR PHARMACEUTICS

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) R. Willemze et al.   ANNALS OF ONCOLOGY

Histone deacetylase inhibitors in lymphoma

(2010) Amanda Copeland et al.   CURRENT OPINION IN ONCOLOGY

Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

(2010) Frederick Lansigan et al.   DRUGS

Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies

(2010) Nitin Jain et al.   EXPERT OPINION ON PHARMACOTHERAPY

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

(2010) Jasmine Zain et al.   INVESTIGATIONAL NEW DRUGS

Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2010) Rafael F. Duarte et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Pitavastatin calcium, vigabatrin, and romidepsin

(2010) Daniel A. Hussar et al.   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

The Emerging Role of Histone Deacetylase Inhibitors in Treating T-cell Lymphomas

(2010) Steven M. Horwitz   Current Hematologic Malignancy Reports

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome

(2009) P. L. Zinzani et al.   ANNALS OF ONCOLOGY

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

(2009) P. T. Bradford et al.   BLOOD

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

(2009) Susan E. Bates et al.   BRITISH JOURNAL OF HAEMATOLOGY

Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma

(2009) S. Woo et al.   CLINICAL CANCER RESEARCH

Update on treatment of cutaneous T-cell lymphoma

(2009) Jennifer M Gardner et al.   CURRENT OPINION IN ONCOLOGY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

(2008) Gaëlle Quereux et al.   ARCHIVES OF DERMATOLOGY

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

(2008) A. Newbold et al.   MOLECULAR CANCER THERAPEUTICS

Mycosis fungoides

(2007) Pier Luigi Zinzani et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY